Key Points
- Director Brad Hively sold 13,333 shares on December 15 at an average price of $3.77 for a total of $50,265.41, cutting his stake by 1.91% to 683,721 shares; the transaction was disclosed in an SEC filing.
- The company reported quarterly EPS of ($0.14) (missing estimates by $0.02) while revenue of $136.56 million beat expectations, though Oncology Institute shows a negative net margin (13.21%) and a deeply negative return on equity.
- Shares trade near $3.84 with a 50/200-day moving average of $3.74/$3.41 and a market cap of about $378M; analysts have a consensus rating of "Moderate Buy" with a $6.50 target.
-logo-1200x675.png?v=20220303080937)
The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) Director Brad Hively sold 13,333 shares of the stock in a transaction on Monday, December 15th. The shares were sold at an average price of $3.77, for a total transaction of $50,265.41. Following the transaction, the director owned 683,721 shares in the company, valued at $2,577,628.17. This trade represents a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Oncology Institute Price Performance
TOI opened at $3.84 on Wednesday. The company has a 50-day moving average of $3.74 and a 200-day moving average of $3.41. The company has a market capitalization of $377.78 million, a P/E ratio of -6.00 and a beta of 0.16. The Oncology Institute, Inc. has a 1-year low of $0.17 and a 1-year high of $4.88. The company has a debt-to-equity ratio of 14.58, a quick ratio of 1.39 and a current ratio of 1.68.
Oncology Institute (NASDAQ:TOI - Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The company had revenue of $136.56 million for the quarter, compared to the consensus estimate of $122.63 million. Oncology Institute had a negative return on equity of 1,527.21% and a negative net margin of 13.21%.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the stock. ProShare Advisors LLC acquired a new stake in Oncology Institute in the second quarter worth $25,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Oncology Institute in the 2nd quarter worth about $32,000. Cetera Investment Advisers lifted its position in Oncology Institute by 35.0% in the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company's stock valued at $36,000 after purchasing an additional 4,545 shares during the last quarter. State of Wyoming acquired a new position in Oncology Institute during the 2nd quarter valued at about $37,000. Finally, Prelude Capital Management LLC acquired a new position in Oncology Institute during the 3rd quarter valued at about $41,000. 36.86% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on the company. BTIG Research reiterated a "buy" rating and issued a $7.00 target price on shares of Oncology Institute in a research report on Tuesday, October 21st. Weiss Ratings restated a "sell (d-)" rating on shares of Oncology Institute in a research note on Wednesday, October 8th. Finally, Needham & Company LLC started coverage on shares of Oncology Institute in a research note on Tuesday, November 25th. They set a "buy" rating and a $5.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Oncology Institute presently has a consensus rating of "Moderate Buy" and a consensus target price of $6.50.
Get Our Latest Stock Report on Oncology Institute
About Oncology Institute
(
Get Free Report)
The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
